1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Vinogradova, O.
Haas, T.
Plow, E.F.
Qin, J.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
1
90.00
90.00
90.00
1.000
1.000
1.000
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
US
Proc.Natl.Acad.Sci.USA
PNASA6
0040
0027-8424
97
1450
1455
10.1073/pnas.040548197
10677482
A structural basis for integrin activation by the cytoplasmic tail of the alpha IIb-subunit.
2000
10.2210/pdb1dpq/pdb
pdb_00001dpq
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
2343.505
INTEGRIN ALPHA-IIB SUBUNIT
CYTOPLASMIC DOMAIN
P1029A/P1030A
1
syn
polymer
no
no
KVGFFKRNRAALEEDDEEGE
KVGFFKRNRAALEEDDEEGE
A
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
database_2
pdbx_nmr_exptl_sample_conditions
pdbx_nmr_software
pdbx_struct_assembly
pdbx_struct_oper_list
struct_ref_seq_dif
repository
Initial release
Version format compliance
Version format compliance
Data collection
Database references
Derived calculations
Experimental preparation
1
0
2000-02-28
1
1
2008-04-27
1
2
2011-07-13
1
3
2021-11-03
_database_2.pdbx_DOI
_database_2.pdbx_database_accession
_pdbx_nmr_exptl_sample_conditions.pressure_units
_pdbx_nmr_software.name
_struct_ref_seq_dif.details
SOLUTION STRUCTURE OF THE INTEGRIN ALPHA IIB CYTOPLASMIC DOMAIN
RCSB
Y
RCSB
1999-12-27
REL
THE PEPTIDE WAS CHEMICALLY SYNTHESIZED. THE SEQUENCE OF RESIDUES IS NATURALLY FOUND IN THE PLATELETS OF HOMO SAPIENS (HUMAN).
sample
DEUT. DPC(DODECYL-PHOSPHOCHOLINE) MICELLES USED
back calculated data agree with experimental NOESY spectrum
30
11
2D NOESY
DQF-COSY
2D TOCSY
50 mM NACL
5.0
1
atm
298
K
simulated annealing
1
minimized average structure
3 MM PEPTIDE
VARIAN
collection
VNMR
5.5
DELAGIO, F.
processing
NMRPipe
GARRETT, D.S.
data analysis
PIPP
BRUNGER, A.T.
structure solution
X-PLOR
3.2
BRUNGER, A.T.
refinement
X-PLOR
3.2
500
Varian
INOVA
LYS
1
n
1
LYS
1
A
VAL
2
n
2
VAL
2
A
GLY
3
n
3
GLY
3
A
PHE
4
n
4
PHE
4
A
PHE
5
n
5
PHE
5
A
LYS
6
n
6
LYS
6
A
ARG
7
n
7
ARG
7
A
ASN
8
n
8
ASN
8
A
ARG
9
n
9
ARG
9
A
ALA
10
n
10
ALA
10
A
ALA
11
n
11
ALA
11
A
LEU
12
n
12
LEU
12
A
GLU
13
n
13
GLU
13
A
GLU
14
n
14
GLU
14
A
ASP
15
n
15
ASP
15
A
ASP
16
n
16
ASP
16
A
GLU
17
n
17
GLU
17
A
GLU
18
n
18
GLU
18
A
GLY
19
n
19
GLY
19
A
GLU
20
n
20
GLU
20
A
author_defined_assembly
1
monomeric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
identity operation
0.0000000000
0.0000000000
0.0000000000
1
A
A
O
H
GLU
ASP
14
16
1.54
2
A
A
O
H
GLU
ASP
14
16
1.53
3
A
A
O
H
ASP
GLU
16
20
1.54
3
A
A
O
H
GLU
ASP
14
16
1.57
4
A
A
O
H
GLU
ASP
14
16
1.55
8
A
A
O
H
GLU
ASP
14
16
1.49
1
A
VAL
2
34.33
47.38
1
A
ARG
9
-57.42
-9.19
1
A
LEU
12
72.60
41.72
1
A
ASP
15
-68.20
53.15
1
A
ASP
16
-69.77
38.53
2
A
VAL
2
34.38
46.28
2
A
ARG
9
-53.98
-8.11
2
A
LEU
12
80.35
40.18
2
A
ASP
15
-68.10
50.83
2
A
ASP
16
-70.08
37.93
3
A
VAL
2
23.22
48.49
3
A
ARG
9
-53.00
-8.08
3
A
LEU
12
81.13
40.26
3
A
ASP
15
-67.14
60.31
3
A
ASP
16
-70.84
36.79
4
A
VAL
2
34.21
46.92
4
A
ARG
9
-58.24
-7.77
4
A
LEU
12
79.92
40.10
4
A
ASP
15
-66.18
60.27
4
A
ASP
16
-70.50
37.92
5
A
VAL
2
22.00
51.45
5
A
ARG
9
-51.63
-8.82
5
A
LEU
12
73.12
41.30
5
A
ASP
16
-70.32
38.53
6
A
VAL
2
34.21
47.56
6
A
ARG
9
-53.24
-8.40
6
A
LEU
12
115.32
23.56
6
A
GLU
13
78.37
37.19
6
A
ASP
16
-70.48
39.24
7
A
VAL
2
33.99
47.09
7
A
ARG
9
-52.94
-9.05
7
A
LEU
12
73.29
41.46
7
A
GLU
14
-46.03
-71.12
7
A
ASP
15
-65.62
67.24
7
A
ASP
16
-71.67
36.01
8
A
VAL
2
23.14
48.28
8
A
ARG
9
-55.35
-6.83
8
A
LEU
12
83.00
40.98
8
A
ASP
15
-66.51
50.83
8
A
ASP
16
-71.71
39.87
9
A
VAL
2
22.88
48.76
9
A
ARG
9
-54.84
-8.88
9
A
LEU
12
70.69
40.65
9
A
GLU
14
-56.15
-84.85
9
A
ASP
16
-73.93
28.30
10
A
VAL
2
34.02
47.76
10
A
ARG
9
-58.69
-8.82
10
A
LEU
12
72.82
40.91
10
A
ASP
15
45.68
71.44
10
A
ASP
16
-142.77
31.14
11
A
VAL
2
34.25
47.21
11
A
ARG
9
-55.26
-6.78
11
A
LEU
12
115.31
22.30
11
A
GLU
13
80.80
36.54
11
A
ASP
16
-71.85
38.98
minimized average
SOLUTION STRUCTURE OF THE CONSTITUTIVELY ACTIVE MUTANT OF THE INTEGRIN ALPHA IIB CYTOPLASMIC DOMAIN.
1
N
N
A
VAL
2
A
VAL
2
HELX_P
A
ALA
10
A
ALA
10
1
1
9
CELL ADHESION
HELIX, CELL ADHESION
ITA2B_HUMAN
UNP
1
P08514
1020
1039
1DPQ
1
20
P08514
A
1
1
20
1
PRO
engineered mutation
ALA
10
1DPQ
A
P08514
UNP
1029
10
1
PRO
engineered mutation
ALA
11
1DPQ
A
P08514
UNP
1030
11
1
P 1